I CFD sono strumenti complessi e presentano un alto rischio di perdere soldi rapidamente a causa della leva finanziaria. Il 74% dei conti di clienti al dettaglio perde denaro facendo trading con i CFD con questo fornitore. Devi verificare se comprendi pienamente come funzionano i CFD e se puoi permetterti di correre il rischio elevato di perdere i tuoi soldi.

Close

Fai trading su BioNTech BNTX

Vendi
 Acquista

Grafico live di BioNTech

5m 15m 30m 1h 4h 1d 1w

Fondamentali dello strumento

Weekly Search
Weekly
Daily
Data Chiudi Variazione variazione % Apertura Massimo Minimo

Le ultime notizie

Closing 2024
2024 Dec 26, 17:00

La prossima settimana:Chiusura del 2024 e primi dati economici del 2025

Forex Indici
UK GDP
Dyogenes Diniz 2024 Dec 19, 16:00

La prossima settimana: Ultima settimana del 2024 sui mercati finanziari

Forex Indici
US interest rate and Europe inflation to guide market direction
Markets.com Support Team 2024 Dec 13, 22:00

La prossima settimana: I tassi di interesse USA e l’inflazione in Europa determineranno la direzione dei mercati

Forex Indici
Dyogenes Diniz 2024 Dec 05, 16:00

La prossima settimana: L’inflazione e i tassi di interesse condizioneranno i mercati questa settimana

Forex Indici
US Employment Rate
Markets.com Support Team 2024 Nov 28, 17:00

La prossima settimana: L’occupazione USA probabilmente guiderà il sentiment sul mercato questa settimana.

Forex Indici
Eurozone inflation
Markets.com Support Team 2024 Nov 23, 16:00

La prossima settimana: I dati sull’inflazione nell’area euro probabilmente confermeranno il taglio di dicembre dei tassi della BCE

Forex Indici
Nvidia Blackwell AI Chips
Markets.com Support Team 2024 Nov 14, 16:00

L’importante rally dei titoli del tech in parte dipenderà dalle trimestrali di Nvidia che verranno pubblicate mercoledì.

Forex Indici
Markets.com Support Team 2024 Nov 07, 16:00

La prossima settimana: Trump trade, dati sull’inflazione e trimestrali di Disney

Forex Indici

Informazioni

Spread

0.7801

Spread (%)

0.8393 %

Leva

1:5

Interesse overnight acquisto

-0.0597 %

Interesse overnight vendita

-0.0292 %

Valuta

USD

Orari di trading

Markets closed

Venerdì

13:31 - 19:59

Lunedì

13:31-19:59

Martedì

13:31-19:59

Mercoledì

13:31-19:59

Giovedi

13:31-19:59

Analisi e statistiche

Apertura

---

Chiusura precedente

---

Massimo/Minimo di 52 settimane

--- – ---

Capitalizzazione di mercato

23202729984

Azioni in circolazione

240392992

Data delle trimestrali (prossima)

0000-00-00

Rendimento da dividendo

2022-06-17

Data ex dividendo

2022-06-02

Tasso di dividendo annuale a termine

0

Rendimento del dividendo annuale a termine

0

EPS

-3.03

Scopri di più su questo strumento

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Strumenti correlati

Asset
Vendi
Acquista
variazione %

Fai trading ora

Fai trading ora

Fai trading ora

Fai trading ora
Strumenti correlati
Trustpilot
RequestMessages7TimelineExceptionsViews0RouteQueries0Models0MailsGateSession
SettingsRequest history38.1.18PHP Version30.21msRequest Duration2MBMemory UsageGET params
status
200 OK
full_url
https://web-qa.staging.markets.com/params
controller_action
App\Http\Controllers\TrackingParams@fetch
Theme
Open Button Position
Hide Empty Tabs
Autoshow
Reset to defaults
status
200 OK
full_url
https://web-qa.staging.markets.com/params
action_name
controller_action
App\Http\Controllers\TrackingParams@fetch
uri
GET params
controller
App\Http\Controllers\TrackingParams@fetch
file
app/Http/Controllers/TrackingParams.php:11-31
middleware
web
duration
30.43ms
peak_memory
4MB
response
application/json
request_format
html
request_query
[]
request_request
[]
request_headers
  0 of 0   
array:14 [▼
  "cookie" => array:1 [▶
    0 => "mktloc=eyJpdiI6ImxEemQ3aXJPQk5UM2tvYnoyVEtPaGc9PSIsInZhbHVlIjoiRmE3ZXpCbDdrTjFpMjNIUzZoQjk5WkVLeWdSWmlWZ3IxRHVuQ0kzN005N280WE1lTU9aY2hpWEo4MldSM0VKViIsIm1hYyI6IjM3ZmFjNmY4MmUyNjcyZDcyNTE5OWU1OTFlOTExOTJmMGVkZjQ4NmQxOTk1MTMwZDhiM2MyOWFjMzk0NWY4YjQiLCJ0YWciOiIifQ%3D%3D; firstURL=https://web-qa.staging.markets.com/sv/instrument/fuelcell/; lastURL=https://web-qa.staging.markets.com/sv/instrument/fuelcell/; mktv4_ip_override=it; XSRF-TOKEN=eyJpdiI6IkJJY3ZGa3pKSkFBenFiYzNmWk9vcWc9PSIsInZhbHVlIjoiWHc1Mk9FdnhBb1JxazdPOWJTZVE2cW13WjFwcURReXBRZFVlcGVuZ2FnaWNER21wOWFaMm1iTHpNaEtxMTBBR0ZaOENKQldESVFsUi9yMzgvdytGeWpUU1pYU3hRbHA4RnYwNDllc2Z5RllWRmw4R1BOMjQxNmpPSU9KWklnNlMiLCJtYWMiOiIxZDc3ZTkyNmU1NDBlMzBmMTk2OGFmMTQzNTFmN2E0YmYyZTlmZGU4OGY4MzdlY2Y2NmNmMGU4YThjZjE1M2UxIiwidGFnIjoiIn0%3D; laravel_session=eyJpdiI6InAzOGNxOE03VUVlVytoZGdtOVJhWnc9PSIsInZhbHVlIjoia0hkcHFSc3dhZ0JCWFgxOVdOOG44WWd2dUNyaU1pZTYxb2FEQTVNSDh6eC9hZFlac2lueTNaa0VQeittNjkxVUVMRTBOTjVCU3dneUpaTHYxQ1pHL0UvODRLYXAydng2MGhiNUszSDcwNmtaZm91aUFSYjROdlpLSklqUVVXbnciLCJtYWMiOiJkMjA0ZWZjYThmMTE0OGMyMzQ2ODRhNzU3Zjk0NmY2MmU0OWE3ZTdlNTU3NGRiOWMwY2I0OWVmMmYwZDY5ODA1IiwidGFnIjoiIn0%3D; intent_group=%252Fit%252Finstrument%252Fbiontech%252F; intent_instrument=biontech ◀mktloc=eyJpdiI6ImxEemQ3aXJPQk5UM2tvYnoyVEtPaGc9PSIsInZhbHVlIjoiRmE3ZXpCbDdrTjFpMjNIUzZoQjk5WkVLeWdSWmlWZ3IxRHVuQ0kzN005N280WE1lTU9aY2hpWEo4MldSM0VKViIsIm1hYyI6I ▶"
  ]
  "accept-encoding" => array:1 [▶
    0 => "gzip, deflate, br, zstd"
  ]
  "sec-fetch-dest" => array:1 [▶
    0 => "empty"
  ]
  "sec-fetch-mode" => array:1 [▶
    0 => "cors"
  ]
  "sec-fetch-site" => array:1 [▶
    0 => "same-origin"
  ]
  "accept" => array:1 [▶
    0 => "*/*"
  ]
  "sec-ch-ua-mobile" => array:1 [▶
    0 => "?0"
  ]
  "sec-ch-ua" => array:1 [▶
    0 => ""HeadlessChrome";v="129", "Not=A?Brand";v="8", "Chromium";v="129""
  ]
  "user-agent" => array:1 [▶
    0 => "Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)"
  ]
  "sec-ch-ua-platform" => array:1 [▶
    0 => ""Windows""
  ]
  "cache-control" => array:1 [▶
    0 => "no-cache"
  ]
  "pragma" => array:1 [▶
    0 => "no-cache"
  ]
  "connection" => array:1 [▶
    0 => "keep-alive"
  ]
  "host" => array:1 [▶
    0 => "web-qa.staging.markets.com"
  ]
]
request_cookies
  0 of 0   
array:8 [▼
  "mktloc" => "us,us"
  "firstURL" => null
  "lastURL" => null
  "mktv4_ip_override" => null
  "XSRF-TOKEN" => "6WSPwGZkuf3FrxzVzCOUciV7qfztvpar5A2JJ3de"
  "laravel_session" => "4lb0LevMOQkOeJrIn40zXeUZvRUL2CRETHeAzgRp"
  "intent_group" => null
  "intent_instrument" => null
]
response_headers
  0 of 0   
array:3 [▼
  "cache-control" => array:1 [▶
    0 => "no-cache, private"
  ]
  "date" => array:1 [▶
    0 => "Sun, 13 Apr 2025 15:23:21 GMT"
  ]
  "content-type" => array:1 [▶
    0 => "application/json"
  ]
]
session_attributes
  0 of 0   
array:4 [▼
  "_token" => "6WSPwGZkuf3FrxzVzCOUciV7qfztvpar5A2JJ3de"
  "PHPDEBUGBAR_STACK_DATA" => []
  "_previous" => array:1 [▶
    "url" => "https://web-qa.staging.markets.com/csrf"
  ]
  "_flash" => array:2 [▶
    "old" => []
    "new" => []
  ]
]
    • Booting (15.77ms)time
    • Application (14.43ms)time
    • Routing (513μs)
    • 1 x Booting (52.2%)
      15.77ms
      1 x Application (47.77%)
      14.43ms
      1 x Routing (1.7%)
      513μs
      0 templates were rendered
        uri
        GET params
        middleware
        web
        controller
        App\Http\Controllers\TrackingParams@fetch
        file
        app/Http/Controllers/TrackingParams.php:11-31
        0 statements were executed0μs
              _token
              6WSPwGZkuf3FrxzVzCOUciV7qfztvpar5A2JJ3de
              PHPDEBUGBAR_STACK_DATA
              []
              _previous
              array:1 [ "url" => "https://web-qa.staging.markets.com/csrf" ]
              _flash
              array:2 [ "old" => [] "new" => [] ]
              ClearShow all
              Date ↕MethodURLData
              #12025-04-13 15:23:20GET/it/instrument/biontech/767
              #22025-04-13 15:23:21GET/csrf/ (ajax)
              #32025-04-13 15:23:21GET/params/ (ajax)